Printer Friendly

The Liposome Company Granted Marketing Approval for ABELCET(R) in Canada

PRINCETON, N.J., July 1 /PRNewswire/ -- Canada has become the seventeenth country to grant marketing approval for ABELCET(R) (Amphotericin B Lipid Complex Injection), a proprietary antifungal drug developed by The Liposome Company, Inc. (Nasdaq: LIP0). The approval is also the first granted by Canadian regulatory authorities for the new lipid-based amphotericin B formulations.

ABELCET has been developed by The Liposome Company to treat systemic fungal infections such as candidiasis, aspergillosis and cryptococcal meningitis -- diseases that are associated with fatality rates of up to 90 percent. These fungal infections most often attack patients with suppressed immune systems, usually resulting from AIDS and therapies for cancer, solid organ and bone marrow transplants.

Until the advent of lipid-based products, amphotericin B (the active ingredient in ABELCET) in its conventional form was generally considered to be the drug of choice to combat these infections. However its propensity to cause kidney damage has often severely limited its dosage and, many believe, its efficacy. The Company's innovative lipid-complex technology in ABELCET permits the delivery of much greater amounts of amphotericin B while significantly reducing the risk of kidney toxicity commonly associated with the conventional drug.

Worldwide sales of ABELCET in 1996 were $52.8 million. Since its first approval in February, 1995 ABELCET has been approved for marketing for a variety of first- and second-line indications in several countries. Approval in Canada follows similar actions in 1997 by regulatory agents in France, Italy, Austria and Switzerland. In Canada, the product's initial indication will be for the treatment of aspergillosis in patients who have failed or who are intolerant of conventional amphotericin B therapy. Marketing applications are being reviewed in a number of other countries.

The Liposome Company is a broad-based biopharmaceutical company developing and marketing products based on its knowledge of lipid technology. ABELCET is marketed in the U.S. and other countries for the treatment of severe systemic fungal infections. TLC D-99 and other products are being developed to treat various cancers. Research is being conducted in the area of bioactive lipids that may have therapeutic activity.

Except for historical information, this press release contains forward- looking statements, including but not limited to, statements regarding the review of marketing applications in various countries and the progress of clinical studies of the Company's products. While these statements reflect our best current judgment, they are subject to risks and uncertainties that could cause actual results to vary, including the risk factors identified from time to time in the Company's SEC filings.

This release is also available at http://www.lipo.com

SOURCE The Liposome Company, Inc.
 -0- 07/01/97


/CONTACT: Brooks Boveroux, Vice President of The Liposome Company, 609-452-7060; or Media: Ernie Knewitz, Ext. 204 or Investor: Barbara Lindheim, Ext. 237, both of Noonan Russo Communications for The Liposome Company, 212-696-4455/

(LIPO)

CO: Liposome Company, Inc. ST: New Jersey IN: MTC SU: PDT

KS-CH -- NYTU066 -- 7147 07/01/97 11:31 EDT http://www.prnewswire.com
COPYRIGHT 1997 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 1, 1997
Words:491
Previous Article:Astrocom Announces Personnel Changes
Next Article:DCR Rates $533,774,986 Chase Commercial Mortgage Securities Corp. Commercial Mortgage Pass-Through Certificates, Series 1997-1
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters